This legislation is designed to improve access to affordable insulin for individuals with diabetes, particularly targeting the financial burdens associated with obtaining this essential medication. It establishes provisions that require health insurance plans to cover selected insulin products without deductibles, ensuring that patients will pay no more than $35 for a 30-day supply starting January 1, 2027. After this date, the maximum cost-sharing may remain at $35 or adjust to 25 percent of the negotiated price, whichever is lower.